On Monday, at 9.30am the share price of this small cap pharma company reached a 52 week-high of ₹2057.15 from previous close of ₹1791.40, gaining around 15% after its quarterly results of Q1 FY25 were published.
What happened: The bullish movement in RPG Life Sciences Ltd.’s share price was driven by its robust revenue growth, which surged 11.93% year-over-year to ₹165.42 crores in Q1 2025 from ₹147.78 crores in Q1 2024. Additionally, on a quarterly basis, the company recorded a substantial 30.26% increase in revenue, climbing from ₹126.99 crores to ₹165.42 crores.
RPG Life Sciences Ltd’s net profit jumped 21.09% to ₹26.76 crores in the Q1 of 2024-2025 from ₹22.10 crores in the same period last year. Furthermore, the Net profit margin increased to 16.17% in Q1 FY2025 from 14.95% in Q1 FY2024.
On a quarterly growth basis, RPG Life Sciences has generated 102.11% jump in its net profits since the last 3 months to ₹26.76 crores in Q1 FY25 from ₹13.24 crores in Q4 FY24. Similarly, the net profit margin increased to 16.17% in Q1 FY25 from 10.42% in the previous quarter.
Also read
Strategic Initiative: RPG life sciences has planned a capital expenditure of Rs.140 crores to modernise plants and R&D infrastructure. The company’s new Rheumatology Franchise now accounts for over 10% of its specialty business contribution.
Revenue Segmentation: RPG Life Sciences earns 67% of its revenues from Domestic Formulations Segment, 18% from International Formulations Segment and 15% from APIs Segment.
International Formulations: RPG Life Sciences exports to over 50 countries, including regions in Europe, Latin America, and Southeast Asia.The international formulations business achieved sales revenue of approximately ₹92.16 crores, marking an 18.3% growth over the previous year.
Shareholding Pattern: The promoters of the company hold 72.82 percent of the shares, followed by 1.15 percent held by Foreign Institutional Investors, 2.61 percent held by Domestic Institutional Investor and the rest 23.44 percent is held by the Public.
Important Financial Ratios: As a result of increase in net profit and revenue on a YoY basis, key financial ratios including ROCE (Return on Capital Employed) and ROE (Return on Equity) have shown improvement.
Specifically, ROCE rose to 31.0% in FY2024 from 29.7% in FY2023, while ROE increased to 23.4% in FY2024 from 22.0% in FY2023.
Company Profile : RPG Life Sciences Ltd is a part of RPG group which is a diversified conglomerate with interests in areas of infrastructure, tyres, information technology, pharmaceuticals, energy and plantations.
The company is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in the domestic and international market.
Written by – Siddesh S Raskar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
